<DOC>
	<DOC>NCT00995618</DOC>
	<brief_summary>This is a randomized, double-blind, 3-period crossover phase 2 study in patients with documented hyperuricemia to evaluate the effect of tranilast on febuxostat pharmacokinetics (PK) and pharmacodynamics (PD) and to evaluate the effect of febuxostat on tranilast PK and PD as measured by reduction in serum uric acid levels.</brief_summary>
	<brief_title>Study of Tranilast Alone or in Combination With Febuxostat in Patients With Hyperuricemia</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Febuxostat</mesh_term>
	<mesh_term>Tranilast</mesh_term>
	<criteria>Male or female, aged 18 to 70 Subjects with hyperuricemia who are otherwise healthy Pregnant or nursing Known history of gout Clinically significant infection at Screening Known sensitivity to tranilast or febuxostat</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Gout</keyword>
	<keyword>Hyperuricemia</keyword>
</DOC>